AI used with MRI for the diagnosis of prostate cancer

" This initiative falls under the medical and diagnostic equipment industry category and is set within London. The procurement process commenced on 20th January 2026, with a preliminary market consultation (PMC) already scheduled for completion by 29th January 2026. The procurement aims to inform the NHS commercial strategy for integrating artificial intelligence in medical imaging, specifically MRI for prostate cancer diagnosis.

Any financial projections in the notice are nominal, with final figures yet to be determined, and interested parties must register via the Atamis e-sourcing portal to participate. This tender offers significant growth opportunities for businesses specialising in medical equipment, diagnostic devices, and AI-driven healthcare solutions. Companies capable of developing or providing MRI imaging equipment, medical software, and diagnostic supplies, particularly those with a focus on prostate cancer detection, are well-suited to engage.

The project also reserves potential involvement for small and medium enterprises (SMEs) and voluntary, community, and social enterprises (VCSEs), making it inclusive for diversified industry players aiming to collaborate with a central government body like NHS England. With the contract period slated between 1st July 2027 and 30th June 2028, businesses have ample time to prepare and align their offerings with NHS requirements.